Economic impact of alternative adjuvant chemotherapy regimens for stage III colon cancer.
BACKGROUND
Adjuvant treatment of stage III colon cancer represents a significant economic burden for the German health care system. The available chemotherapy regimens have significantly different medical and economic profiles.


METHODS
A modeling study based on published clinical trials was performed to assess costs of 5 different regimens (Mayo Clinic, LV5FU2, FOLFOX-4, Xelox, Capecitabine) from the perspective of the statutory sickness funds. Costs were calculated based on the assumption that patients were treated exactly according to a standardized clinical pathway.


RESULTS
Total costs are highest for FOLFOX-4 (H22,034/patient) and Xelox (H21,411). Lowest costs of the oxaliplatin-free treatments are associated with capecitabine (H4,935), followed by the Mayo Clinic (H6,426) and LV5FU2 protocols (H8,336). The main driver of costs in all instances is drug acquisition (90% of total costs), whereas costs of diagnostics or complications have no major impact (0.5-2%).


CONCLUSIONS
In Germany, FOLFOX-4 is the most effective but also the most expensive treatment and represents the current standard. Xelox emerges as a slightly less costly alternative when oral treatment is preferred. For patients not able to tolerate oxaliplatin-based therapy, capecitabine has the best economic profile of all alternative regimens. Drug acquisition costs are by far the most important factor driving costs in all regimens.
Goerner
Martin
M
Department of Hematology, Oncology & Palliative Care, Community Hospital Bielefeld, Germany. martin.goerner@sk-bielefeld.de
Riemer-Hommel
Petra
P
D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000191:economics* / Q000706:statistics & numerical data; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000453:epidemiology*; D005858:Germany / Q000453:epidemiology; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D015994:Incidence
D000970:Antineoplastic Agents